RETINAL VASCULAR ABNORMALITIES RELATED TO NEUROFIBROMATOSIS TYPE 1: Natural History and Classification by Optical Coherence Tomography Angiography in 473 Patients.


Journal

Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919

Informations de publication

Date de publication:
01 May 2021
Historique:
pubmed: 25 8 2020
medline: 15 12 2021
entrez: 25 8 2020
Statut: ppublish

Résumé

To analyze and classify neurofibromatosis Type 1 (NF1)-related retinal vascular abnormalities (RVAs), their natural history and correlation with disease severity, in a large cohort of patients. This was an observational longitudinal study with prospective enrollment. Four hundred and seventy-three patients affected by NF1 and 150 age-matched healthy subjects were consecutively enrolled. Retinal vascular abnormalities were detected by means of near-infrared reflectance and studied by optical coherence tomography angiography. The superficial vascular plexus and the deep vascular complex (DVC) were quantitatively and qualitatively analyzed. We identified RVAs in 82 of 473 (17%) NF1 patients, but in none of the 150 healthy subjects. A comparison revealed that NF1 patients with RVAs showed a higher number of NF1 diagnostic criteria (4.3 ± 1.5 vs. 3.9 ±1.5, respectively; P = 0.02) than patients without RVAs. Three different RVA types were identified on optical coherence tomography angiography: macrovascular angiomatosis of the sole superficial vascular plexus; macrovascular angiomatosis of the superficial vascular plexus combined with microvascular angiomatosis of the deep vascular complex; and combined macrovascular angiomatosis of both superficial vascular plexus and deep vascular complex. The prospective analysis of optical coherence tomography angiography images showed no significant longitudinal evolution of RVAs (mean follow-up: 3.7 ± 2.8 years). A single patient developed a de novo single RVA, and two RVAs showed detectable changes during follow-up. In NF1 patients, RVAs are a characteristic sign that correlates with a more severe systemic disease expression, usually remaining stable during time. Optical coherence tomography angiography allows for the identification of different RVAs subtypes.

Identifiants

pubmed: 32833785
pii: 00006982-202105000-00011
doi: 10.1097/IAE.0000000000002962
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

979-986

Références

Wu-Chou YH, Hung TC, Lin YT, et al. Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis. J Biomed Sci 2018; 25:72.
National Institutes of Health Consensus development conference statement: neurofibromatosis. Bethesda, MD, USA, 1987. Neurofibromatosis 1988;1:172–178.
Vaassen P, Rosenbaum T. Nevus anemicus as an additional diagnostic marker of neurofibromatosis type 1 in childhood. Neuropediatrics 2016;47:190–193.
Tadini G, Milani D, Menni F, et al. Is it time to change the neurofibromatosis 1 diagnostic criteria? Eur J Intern Med 2014;25:506–510.
Parrozzani R, Clementi M, Frizziero L, et al. Vivo detection of choroidal abnormalities related to NF1: feasibility and comparison with standard NIH diagnostic criteria in pediatric patients. Invest Ophthalmol Vis Sci 2015; 56:6036–6042.
Parrozzani R, Clementi M, Kotsafti O, et al. Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci 2013;54:8112–8118.
Vagge A, Camicione P, Capris C, et al. Choroidal abnormalities in neurofibromatosis type 1 detected by near-infrared reflectance imaging in paediatric population. Acta Ophthalmol 2015;93:e667–e671.
Viola F, Villani E, Natacci F, et al. Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. Ophthalmology 2012;119:369–375.
Parrozzani R, Pilotto E, Clementi M, et al. Retinal vascular abnormalities IN a large cohort OF patients affected BY neurofibromatosis type 1: a study using optical coherence tomography angiography. Retina (Philadelphia, PA) 2018;38:585–593.
Oderich GS, Sullivan TM, Bower TC, et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. J Vasc Surg 2007;46:475–484.
Muci-Mendoza R, Ramella M, Fuenmayor-Rivera D. Corkscrew retinal vessels in neurofibromatosis type 1: report of 12 cases. Br J Ophthalmol 2002;86:282–284.
Moramarco A, Giustini S, Miraglia E, et al. NIR modality to diagnose retinal microvascular abnormalities in neurofibromatosis type 1. Graefes Arch Clin Exp Ophthalmol 2018;256:1789–1790.
Abdolrahimzadeh S, Felli L, Piraino DC, et al. Retinal microvascular abnormalities overlying choroidal nodules in neurofibromatosis type 1. BMC Ophthalmol 2014;14:146.
Makino S, Endoh K, Tampo H. Retinal microvascular abnormalities in neurofibromatosis type 1 associated with congenital retinal macrovessels. Case Rep Ophthalmol Med 2013;2013:604191.
de Blank PMK, Fisher MJ, Liu GT, et al. Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol 2017;37:S23–S32.
Campbell JP, Zhang M, Hwang TS, et al. Detailed vascular anatomy of the human retina by projection-resolved optical coherence tomography angiography. Sci Rep 2017;7:42201.
Moramarco A, Miraglia E, Mallone F, et al. Retinal microvascular abnormalities in neurofibromatosis type 1. Br J Ophthalmol 2019;103:1590–1594.
An D, Balaratnasingam C, Heisler M, et al. Quantitative comparisons between optical coherence tomography angiography and matched histology in the human eye. Exp Eye Res 2018;170:13–19.
Kim AY, Chu Z, Shahidzadeh A, et al. Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical coherence tomography angiography. Invest Ophthalmol Vis Sci 2016;57:OCT362–OCT370.
Parrozzani R, Frizziero L, Londei D, et al. Peripapillary vascular changes in radiation optic neuropathy: an optical coherence tomography angiography grading. Br J Ophthalmol 2018;102:1238–1243.
Ahlgren-Beckendorf JA, Maggio WW, Chen F, Kent TA. Neurofibromatosis 1 mRNA expression in blood vessels. Biochem Biophys Res Commun 1993;197:1019–1024.
Cassiman C, Casteels I, Stalmans P, et al. Optical coherence tomography angiography of retinal microvascular changes overlying choroidal nodules in neurofibromatosis type 1. Case Rep Ophthalmol 2017;8:214–220.
Battiston AJ, Dalvin LA, Shields CL. Neurofibromatosis type-1 with retinal microvascular corkscrew tortuosity. Indian J Ophthalmol 2019;67:2054–2055. Hamilton SJ, Friedman JM. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet 2000;58:341–344.
Hamilton SJ, Friedman JM. Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet 2000;58:341–344.
Bajaj A, Li QF, Zheng Q, Pumiglia K. Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis. PLoS One 2012;7:e49222.
Zhang H, Hudson FZ, Xu Z, et al. Neurofibromin deficiency induces endothelial cell proliferation and retinal neovascularization. Invest Ophthalmol Vis Sci 2018;59:2520–2528.

Auteurs

Raffaele Parrozzani (R)

Department of Ophthalmology, University of Padova, Padova, Italy.

Luisa Frizziero (L)

IRCCS-Fondazione Bietti, Rome, Italy.

Sara Trainiti (S)

Department of Ophthalmology, University of Padova, Padova, Italy.

Andrea Calciati (A)

Department of Ophthalmology, University of Padova, Padova, Italy.

Davide Londei (D)

Department of Ophthalmology, University of Padova, Padova, Italy.

Giacomo Miglionico (G)

Department of Ophthalmology, University of Padova, Padova, Italy.

Eva Trevisson (E)

Department of Women's and Children's Health, Clinical Genetics Unit, University of Padova, Padova, Italy ; and.

Giulia Midena (G)

Institute of Ophthalmology, Policlinico Gemelli, IRCCS, Rome, Italy .

Elisabetta Pilotto (E)

Department of Ophthalmology, University of Padova, Padova, Italy.

Edoardo Midena (E)

Department of Ophthalmology, University of Padova, Padova, Italy.
IRCCS-Fondazione Bietti, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH